Quantum-Si Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

QSI 11.18.2024

Full Press ReleaseSEC FilingsOur QSI Tweets

About Gravity Analytica

Recent News

  • 01.22.2025 - Microproteins and the Dark Proteome: Tiny Molecules with Big Potential
  • 01.22.2025 - Quantum-Si’s Innovative Protein Barcoding Enhances Next-Gen Screening for mRNA Therapeutics
  • 01.20.2025 - Quantum-Si Showcases Advances in Multiomics at the Festival of Genomics UK

Recent Filings

    BRANFORD, Conn.--(BUSINESS WIRE)--Nov. 18, 2024--Quantum-Si Incorporated(Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing CompanyTM, today announced that the Compensation Committee of Quantum-Si’s Board of Directors has granted 340,460 restricted stock units (“RSUs”) to a new employee under the Company’s previously adoptedQuantum-Si Incorporated2023 Inducement Equity Incentive Plan, as amended (the “2023 Inducement Plan”). The RSUs were granted as an inducement material to the new employee becoming an employee ofQuantum-Siin accordance with Nasdaq Listing Rule 5635(c)(4).

    The 2023 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously employees ofQuantum-Si(or following a bona fide period of non-employment), as an inducement material to such individuals’ entering into employment withQuantum-Si, pursuant to Rule 5635(c)(4) of the Nasdaq Listing Rules.

    The RSUs will vest as to 25% onDecember 20, 2025, with the remainder vesting in 12 equal quarterly installments thereafter, subject to the employee’s continued employment withQuantum-Sion such vesting dates. The RSUs are subject to the terms and conditions of the 2023 Inducement Plan and an RSU agreement covering the grant.

    AboutQuantum-Si Incorporated

    Quantum-Si,The Protein Sequencing CompanyTM, is focused on revolutionizing the growing field of proteomics. The Company’s Platinum®instrument enables Next-Generation Protein SequencingTM that advances proteomic research, drug discovery, and diagnostics beyond what has been possible with existing proteomic tools. Learn more atquantum-si.comor follow us onLinkedInorX.

    View source version onbusinesswire.com:https://www.businesswire.com/news/home/20241118913045/en/

    Investor ContactDoug Farrell, VP, Investor Relationsir@quantum-si.com

    Media ContactKatherine Atkinson, SVP, Commercial Marketingmedia@quantum-si.com

    Source:Quantum-Si Incorporated

    Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com